Cardiff University scientists have discovered two genes linked to a person's risk of developing Alzheimer's, which could help in the hunt to find a cure for the disease.
Researchers behind the "exciting" discovery hope it will lead to new treatments for the condition which currently affects more than half a million people in the UK, according to the Alzheimer's Society, and is the leading cause of dementia.
Dr Rebecca Sims, from Cardiff University's School of Medicine, said the genes, which suggested immune cells in the brain played a causal role in the disease, were "very good" targets for potential drug treatment.
Dr Doug Brown, director of research and development at the Society which jointly funded the work, said: "Over 60% of people with dementia have Alzheimer's disease, yet despite its prevalence we still don't fully understand the complex causes of the disease.
Dr Brown said such findings helped to show researchers where to focus their efforts in the search for new, effective treatments.
The researchers from Cardiff University received funding from the Medical Research Council (MRC), Welsh Government and Alzheimer's Research UK.
They identified the two genes, which were not previously considered candidates for Alzheimer's risk, during a study which compared the DNA of tens of thousands of individuals with Alzheimer's with aged-matched people who are free from the disease, building on their previous work of identifying 24 susceptibility genes.
The centre, which will employ up to 60 researchers in the first five years of the initiative and with the potential to be awarded further funding is set to become the biggest investment Wales has ever received for scientific study into dementia.
Dr Rosa Sancho, who is head of research at Alzheimer's Research UK, likened the revelations to "finding puzzle pieces that biologists can start to fit together to build a complete picture of a disease".
She said: "There are currently no treatments to slow the progression of Alzheimer's and increased investment in research is vital so that we can capitalise on new findings and drive progress for people with the condition and their families."